Mesothelin-targeted CD40 agonistic multispecific antibody constructs for the treatment of solid tumors
US11926672B2 · kind B2 · utility
0Cited by
8References
35Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 18, 2020 |
| Grant date | Mar 12, 2024 |
| Priority date | — |
| Expiry date | Sep 22, 2041 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a human agonistic CD40 multispecific antibody construct for treatment of solid tumors by engineering a molecule that specifically targets the CD40 pathway on tumor-associated APCs, without systemic CD40 activation.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.